NCT06241846 2025-08-27
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2 Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Karolinska Institutet
SL VAXiGEN